Epigenetic Changes in Melanoma and the Development of Epigenetic Therapy for Melanoma by Do, Duc P. & Rizvi, Syed A.A.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
2 
Epigenetic Changes in Melanoma and  
the Development of Epigenetic  
Therapy for Melanoma 
Duc P. Do1 and Syed A.A. Rizvi2 
1Department of Pharmaceutical Sciences 
College of Pharmacy, Chicago State University 
2Department of Pharmaceutical Sciences 
College of Pharmacy, Nova Southeastern University  
USA  
1. Introduction 
Melanoma is responsible for 80% of all skin cancer deaths (Miller & Mihm, 2006), and it is 
the most common cause of cancer deaths between the age of 20 and 35 years old (Houghton 
& Polsky, 2002). Melanoma is a highly heterogeneous cancer that is caused by the 
accumulation of genetic and epigenetic defects allowing the cell to escape normal cellular 
controls. Genetic changes are caused by irreversible alterations in the DNA sequence, 
including chromosomal amplification or deletions and gene mutations that culminate in 
aberrant cellular functions, such as activation of oncogenes and inactivation of tumor 
suppressors. However, recent progress in cancer research has shown that epigenetic events 
may play a major role in establishing the correct program of gene expression. Epigenetics is 
defined as heritable changes in gene expression that are not due to any changes in the DNA 
sequence. Currently, four epigenetic drugs, vorinostat (Marks & Breslow, 2007), romidepsin 
(Campas-Moya, 2009), azacitidine (Mani & Herceg, 2010; Wijermans et al., 2005), and 
decitabine (Mani & Herceg, 2010), have been approved for the treatment of hematologic 
malignancies in the United States by the Food and Drug Administration (U.S. FDA).  
In a human cell, there are approximately two meters of diploid DNA that are packaged 
inside the nucleus with a volume of about 1000 μm3 (Kamakaka & Biggins, 2005). This 
packaging of DNA is facilitated by histones. Histones are a group of highly conserved, basic 
(positively-charged) proteins that are rich in arginine and lysine residues. This DNA-protein 
complex is called the chromatin. In chromatin, proteins account for more than half of the 
weight, from which, histone proteins being the most abundant. There are five distinct 
families of histones, each with numerous variants or individual genes. DNA is packaged 
into nucleomes comprising a histone octamer of two copies of each core histones (H2A, H2B, 
H3, and H4) (Luger et al., 1997). The core histones interact in pairs. Two H3:H4 dimers 
interact together forming a tetramer, and two H2A:H2B dimers associate with the H3:H4 
tetramer to form a nucleosome. About 146 bp of DNA is wrapped around a histone octamer. 
One molecule of histone H1 associates at the position where the DNA enters and exits the 
nucleosome core, thus sealing the two turns of DNA (Luger et al., 1997).  
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These core histones contain a conserved C-terminal histone fold domain and unique N-
terminal tails. The histone N-terminal tails protrude from the nucleosome core and provide 
sites for posttranslational modifications, including acetylation, methylation, 
phosphorylation, and ubiquitination (Jenuwein & Allis, 2001). These distinct patterns of 
posttranslational modifications make up the histone code that is read by multiprotein 
chromatin remodelling complexes to determine the transcriptional status of the target gene 
(Strahl & Allis, 2000).  
2. Histone acetylation and histone deacetylases 
Epigenetic phenomena can be viewed as changes in the packaging and modifications of the 
DNA. In the case of DNA, it is modified only by methylation. Changes in the packaging of 
DNA include both histone modifications and chromatin remodeling. Histones can be 
modified by methylation, acetylation, phosphorylation, biotinylation, ubiquitination, 
sumoylation, and ADP-ribosylation. Lysine residues in the histone tails can be acetylated or 
methylated. Arginine residues can be methylated (Howell et al., 2009). 
Among all of the posttranslational modifications on histone tails, histone acetylation is 
among the most extensively studied. In normal cells, acetylation and deacetylation exist in 
equilibrium. Acetylation is a reaction that is catalyzed by histone acetyltransferases (HATs), 
and the deacetylation reaction is catalyzed by histone deacetylases (HDACs). These two 
families of enzymes regulate the delicate balance needed for maintaining the states of 
chromatin and chromatin dynamics (Figure 1).  
Acetylation is a reversible reaction occurring on lysine residues within the N-terminal 
tails of core histones H3 and H4. For histone acetylation, one of the hydrogens in the free 
amino group of internal lysine is substituted with an acetyl (CH3CO) group. The addition 
of an acetyl group removes the positive charge from the NH3+ group on lysine, thus 
neutralizing the basic charge of the histone tails. This modification is suggested to reduce 
the affinity between histones and DNA, which, in turn, correlates with active gene 
expression. Acetylated histone is usually associated with transcriptionally active 
chromatin (Hebbes et al., 1992; Kouzarides, 2007; Turner, 1993). In addition, it is involved 
in many processes, such as replication, nucleosome assembly, higher-order chromatin 
packing and interactions of nonhistone proteins (Grant & Berger, 1999). Lysine at amino 
acid positions 9, 14, 18, and 23 for histone H3 and at amino acid positions 5, 8, 12, 16 for 
histone H4 are frequent targets for acetylation. These histone modifications facilitate 
access and binding of transcription factors. 
Histone deacetylation is associated with an inactive (closed) state of chromatin and 
transcriptional repression (Kouzarides, 2007; Strahl & Allis, 2000). Deacetylation is catalyzed 
by histone deacetylases (HDAC). HDACs catalyze the removal of acetyl groups from lysine 
residues. HDACs and HATs are either part of a multiprotein transcriptional complex or 
interact with DNA binding proteins (Haberland et al., 2009; Jenuwein & Allis, 2001). 
Deregulation in the activity of HDACs and HATs may lead to alterations in gene expression 
and has been linked to diseases, particularly cancers.  Fraga et al (2005) found that the loss of 
acetylation of histone H4 at K16 and K20 is a common hallmark of human cancer. Recently, 
Kondo et al. (2008) found, 5% of the genes are silenced by trimethylation of H3K27 
independent of DNA methylation. 
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Fig. 1. The states of chromatin and regulation of gene expression. HAT: Histone 
acetyltransferase; HDAC: Histone deacetylase. 
To date, 18 HDACs have been identified in humans. They are divided into four classes 
based on their homology to yeast HDACs (Table 1). Class I enzymes, which included 
HDACs 1, 2, 3, and 8, are related to the yeast RPD3 (de Ruijter et al., 2003; Paris et al., 2008). 
Class I HDACs 1, 2, and 3 are ubiquitously expressed and are almost exclusively found in 
the nuclei of cells in various cell lines and tissues (de Ruijter et al., 2003; Paris et al., 2008). 
Unlike HDACs 1-3, HDAC 8 is found only in cells with smooth muscle/myoepithelial 
differentiation. HDAC8 expression was found in smooth muscle cells where its expression is 
suggested to play a role in regulating the dynamics of smooth muscle cytoskeleton 
(Waltregny et al., 2004). These class I HDACs are involved in the regulation of proliferation, 
apoptosis, cardiac morphogenesis, and interferon (INF) expression through regulating gene 
expressions (Bernstein et al., 2000; Foglietti et al., 2006; Zupkovitz et al., 2006). Class II 
proteins, which included HDACs 4, 5, 6, 7, 9, and 10, share domains with the yeast HDAC-1 
(de Ruijter et al., 2003; Paris et al., 2008). Class II HDACs can shuttle between the nucleus 
and the cytoplasm (Paris et al., 2008). Class II HDAC 6 is not seen in lymphocytes, stromal 
cells, and vascular endothelial cells (Yoshida et al., 2004; Zhang et al., 2004). It is localized 
mainly in the cytoplasm. This HDAC6 enzyme is also found on the perinuclear and leading-
edge subcellular regions of cells. It is a microtubule-associated deacetylase (Hubbert et al., 
2002). HDAC 7 inhibits the expression of Nur77, which is involved in the regulation of 
apoptosis and negative selection during developing thymocytes (Dequiedt et al., 2005). 
Unlike class I HDACs, class II HDACs are found only in some tissues. The recently 
described class IV, comprised solely of HDAC 11 enzyme, shares features of classes I and II 
HDACs, such as the dependence on zinc for their enzymatic activity. Classes I, II and IV are 
zinc dependent proteases (de Ruijter et al., 2003; Gao et al., 2002; Glozak & Seto, 2007). Class 
III HDACs (sirtuins) have been identified based on sequence homology with the yeast 
transcription repressor Sir2. To date, seven different sirtuins have been identified, and all of 
the enzymes of class III require NAD+ for their activity. This class of enzymes is localized in 
the nucleus (de Ruijter et al., 2003; Glozak & Seto, 2007). HDACs can deacetylase non-
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histone proteins, such as tumor suppressors (e.g., p53), and signaling molecules (e.g., STAT1 
and STAT3) (Minucci & Pelicci, 2006).  
 
HDAC 
Example of 
Biological 
Functions
Tissue 
Distribution 
Localization Reference 
Class I 
HDAC1 
essential in cell 
survival and 
proliferation 
ubiquitous nucleus 
(Bernstein et al., 
2000; Paris et al., 
2008; Sun & 
Hampsey, 1999) 
HDAC2 
(Foglietti et al., 
2006; Paris et al., 
2008) 
HDAC3 
(Lagger et al., 
2002; Paris et al., 
2008; Zupkovitz et 
al., 2006) 
HDAC8 
(Montgomery et 
al., 2007; Paris et 
al., 2008) 
Class IIa 
HDAC4 
mediator of 
neuronal death
heart; brain; 
skeletal 
muscle 
nucleus/ 
cytoplasm 
(Paris et al., 2008; 
Waltregny et al., 
2004; Waltregny et 
al., 2005) 
HDAC5 
cardiac 
development 
heart; brain; 
skeletal 
muscle
(Bolger & Yao, 
2005; Paris et al., 
2008) 
HDAC7 
regulation of 
apoptosis in 
developing 
thymocytes
heart; skeletal 
muscle; 
pancreas; 
spleen
(Paris et al., 2008; 
Vega et al., 2004) 
HDAC9 
cardiac 
development 
brain; skeletal 
muscle 
(Bolger & Yao, 
2005; Paris et al., 
2008) 
Class IIb 
HDAC6 
regulation of 
tubulin and 
Hsp90 
acetylation 
heart; liver; 
kidney; 
pancreas 
mainly 
cytoplasm 
(Chang et al., 2004; 
Dequiedt et al., 
2003; Paris et al., 
2008; Zhang et al., 
2002) 
HDAC10 
regulation of 
thioredoxin-
interacting 
protein 
expression
spleen; liver; 
kidney 
(Lee et al., 2010) 
Class V HDAC11 
regulation of 
immune 
function
heart; brain; 
skeletal 
muscle; kidney
nucleus/        
cytoplasm 
(Villagra et al., 
2009) 
Table 1. Histone deacetylases. 
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2.1 Clinical applications of histone modifications 
Given the association between HDAC enzymes and cancers, there is growing interest in 
using HDAC inhibitors (HDACI) as antitumor agents. Inhibition of HDAC activity should 
lead to chromatin decondensation and an increase in gene transcription (Figure 1) 
(Karagiannis & El-Osta, 2006). HDACIs have been shown to have pleiotropic effects, 
including cell cycle arrest, growth inhibition and chromatin decondensation. They interfere 
directly with the mitotic spindle checkpoint, differentiation, and apoptosis in cancer cell 
types (Choi et al., 2007; Marchion & Munster, 2007; Stearns et al., 2007; Xu et al., 2005). Imre 
et al. (2006) showed that HDACIs reduce the responsiveness of tumor cells to the tumor 
necrosis factor-ǂ (TNF-ǂ) mediated activation of the nuclear factor-kappa B (NF-kappa B). 
All HDACIs upregulate p21, an important mediator of growth arrest (Richon et al., 2000). 
Studies in clinical trials have attempted to use HDACIs in combination therapy with some 
successes (Johnstone, 2002). This combined strategy has shown promise in some 
malignancies (Bishton et al., 2007).  
To date, more than 18 HDACIs have been tested in clinical trials for cancer therapy (Carew 
et al., 2008; Paris et al., 2008). In the United States, two histone deacetylase inhibitors, 
namely vorinostat (Zolinza) and romidepsin (Istodax), have been approved for the 
treatment of cutaneous T-cell lymphoma. HDACIs are usually classified into various groups 
based on their structures, including hydroxamic acids, cyclic peptides, short chain fatty 
acids, and benzamides. Hydroxamic acid derived compounds (trichostatin A, oxamflatin) 
have been used in clinical trials for treating both hematologic malignancies and solid 
tumors. These compounds contain an acid moiety that can fit into the catalytic site and bind 
to the zinc atom, thus inhibiting the HDAC enzyme (Marchion & Munster, 2007; Marks et 
al., 2000). For cyclic peptide group (depsipeptide, trapoxin), HDACIs are effective in 
nanomolar range. On the other hand, short chain fatty acid compounds (butyrate, 
trybutyrin) require relatively high concentrations for their action. A member of this group, 
valproic acid has been used in antiepileptic treatment. The use of valproic acid as an anti-
epileptic underlines the wide functional distribution of HDACs, contributing to problems 
targeting the cancer treatments using histone deacetylase inhibitors. The benzamide group 
molecules (MS-275, CI-994) exert their action at micromolar concentrations. Since the 
enzymatic pocket is highly conserved in nature, most HDACIs do not selectively inhibit 
individual HDAC enzymes. Rather, HDACIs inhibit several HDAC enzymes 
simultaneously. They target mainly classes I and II HDACs (Marks & Xu, 2009; Paris et al., 
2008). Table 2 shows the histone deacetylase inhibitors. 
Histone deacetylase inhibitors have been investigated in clinical trials for melanoma (Table 
3). A multicenter, phase II clinical trial was conducted to evaluate the efficacy, safety, and 
pharmacokinetics of the histone deacetylase inhibitor, pyridylmethyl-N-{4-[(2-
aminophenyl)-carbamoyl]-benzyl}-carbamate (MS-275) in 28 patients with pretreated 
metastatic melanoma. MS-275 is an oral benzamide HDACI. In the study, patients with 
unresectable American Joint Committee on Cancer (AJCC) stage IV melanoma, refractory to 
at least one earlier systemic therapy, were randomized to receive MS-275 3 mg bi-weekly or 
7 mg weekly on a 28-day cycle. The primary endpoint of the study was objective tumor 
response, and the secondary study endpoints were safety and time-to-progression. No 
objective responses were observed in pretreated metastatic melanoma patients. The median 
time-to-progession was comparable in both arms of the study. MS-275 was well tolearted, 
with nausea, diarrhea, and hypophosphatemia as the most frequently reported adverse 
events (Hauschild et al., 2008).  
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Compound Chemical 
Group 
[Range] HDAC 
Specificity
In Vitro Effect Reference 
Sodium 
butyrate 
Short-chain 
fatty acid 
mM Class I, IIa 
Apoptosis 
Cell-cycle 
arrest 
(Bhalla, 2005; 
Bolden et al., 2006; 
Johnstone, 2002; 
Schwabe & 
Lubbert, 2007) 
Valproic acid 
(VPA) 
Short-chain 
fatty acid 
mM Class I, IIa 
Apoptosis 
Differentiation
(Bhalla, 2005; 
Bolden et al., 2006; 
Johnstone, 2002; 
Schwabe & 
Lubbert, 2007) 
Trichostatin A 
(TSA) 
Hydroxamic 
acid 
nM Class I, IIa 
Apoptosis 
Cell-cycle 
arrest 
Differentiation
(Bhalla, 2005; 
Bolden et al., 2006; 
Johnstone, 2002; 
Schwabe & 
Lubbert, 2007) 
Suberoylanilide 
hydroxamic 
acid (SAHA) or 
vorinostat 
Hydroxamic 
acid 
µM Class I, II 
Apoptosis 
Cell-cycle 
arrest 
(Bhalla, 2005; 
Bolden et al., 2006; 
Johnstone, 2002; 
Schwabe & 
Lubbert, 2007) 
Depsipeptide 
(FK 228) 
Cyclic 
tetrapeptide 
nM Class I 
Apoptosis 
Cell-cycle 
arrest 
(Bhalla, 2005; 
Bolden et al., 2006; 
Johnstone, 2002; 
Schwabe & 
Lubbert, 2007) 
Apicidin 
Cyclic 
tetrapeptide 
nM 
HDACs 1 
and 3 
Apoptosis 
Cell-cycle 
arrest 
(Bolden et al., 
2006; Johnstone, 
2002; Schwabe & 
Lubbert, 2007; 
Vannini et al., 
2004) 
MS-275 Benzamide µM Class I 
Cell-cycle 
arrest 
(Bolden et al., 
2006; Hu et al., 
2003; Johnstone, 
2002; Schwabe & 
Lubbert, 2007) 
Table 2. Histone deacetylase inhibitors 
Due to the low response rates of HDACIs as single-agent therapies, HDACIs have also been 
investigated in combination with other therapeutic agents (Table 3).  In a phase I/II clinical 
trial for patients with stage IV melanoma, the combination of valproic acid and the 
topoisomerase I inhibitor karenitecin associated with disease stabilization in 47% of patients. 
The median overall survival and time-to-progression were 32.8 and 10.2 weeks, respectively. 
In addition, histone hyperacetylation was observed in peripheral blood mononuclear cells 
(Daud et al., 2009). 
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HDACIs have also been investigated in combination with other treatment modalities. A 
phase I/II study of HDACI valproic acid with standard chemoimmunotherapy in patients 
with advanced melanoma was conducted to evaluate its clinical activity and to assess 
toxicity. In the study, patients were treated initialy with valproic acid alone for 6 weeks. 
After the treatment with valproic acid alone, dacarbazine plus interferon-ǂ therapy was 
started in combination with the valproic acid. However, the results showed that the 
combination of valproic acid and chemoimmunotherapy did not produce superior results as 
compared to standard therapy (Rocca et al., 2009). 
 
Epigenetic 
Agent 
Combination Malignancy Phase Reference 
Histone Deacetylase Inhibitors (HDACIs) 
Valproic acid 
Karenitecin 
(topoisomerase 
I inhibitor) 
Melanoma I, II 
(Cang et al., 2009; Howell et 
al., 2009; Sigalotti et al., 
2010) 
Vorinostat 
(Zolinza) 
NPI-0052 
(proteasome 
inhibitor) 
Melanoma I 
(Cang et al., 2009; Howell et 
al., 2009; Sigalotti et al., 
2010) 
Vorinostat 
(Zolinza) 
 
Unresectable 
Metastatic 
Melanoma 
(Stage IV) 
II 
(Cang et al., 2009; Howell et 
al., 2009; Sigalotti et al., 
2010) 
MS-275  Melanoma II 
(Cang et al., 2009; Howell et 
al., 2009; Sigalotti et al., 
2010) 
Romidepsin  
Nonresectable 
Intraocular 
Melanoma or 
Unresectable 
Stage III or 
Stage IV 
Melanoma 
II 
(Cang et al., 2009; Howell et 
al., 2009; Sigalotti et al., 
2010) 
DNA Methyltransferase Inhibitors (DNA Hypomethylating Agents) (DNMTIs) 
5-azacytidine 
(Vidaza) 
Recombinant 
Interferon ǂ-2b Melanoma I 
(Cang et al., 2009; Howell et 
al., 2009; Sigalotti et al., 
2010) 
5-aza-2-
deoxycytidine 
(Dacogen) 
Temozolomide Melanoma I, II 
(Cang et al., 2009; Howell et 
al., 2009; Sigalotti et al., 
2010) 
Pegylated 
Interferon ǂ-2b Melanoma I, II 
(Cang et al., 2009; Howell et 
al., 2009; Sigalotti et al., 
2010) 
Panobinostat, 
Temozolomide 
Melanoma I, II 
(Cang et al., 2009; Howell et 
al., 2009; Sigalotti et al., 
2010) 
Table 3. Current epigenetic agents used in clinical trials for melanoma patients 
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3. DNA methylation 
DNA methylation is carried out by different DNA methyltransferases (DNMT). DNMT1 
involves in the maintenance of established methylation patterns. DNMT3a and DNMT3b are 
implicated in de novo DNA methylation (Bestor, 2000; Okano et al., 1999; Rothhammer & 
Bosserhoff, 2007). This epigenetic event takes place at the C5 position of cytosine on the CpG 
dinucleotide rich regions (CpG islands) that are distributed throughout the genome. Proper 
DNA methylation patterns are essential for human development and normal functioning. In 
normal cells, CpG islands located in the promoter regions are mainly unmethylated; 
however, in melanoma cancer cells, aberrant hypermethylation occur. In addition, genome-
wide hypomethylation occurs in melanoma cancer cells (Jones & Baylin, 2007). This 
epigenetic modification results in silencing the transcription of selected tumor suppressor 
genes (Robertson, 2005; Rothhammer & Bosserhoff, 2007). Aberrant DNA hypermethylation 
of promoter regions has been shown to result in the silencing of at least 50 genes (Fulda et 
al., 2001; Gallagher et al., 2005; Mori et al., 2005; Muthusamy et al., 2006; Paz et al., 2003; 
Rothhammer & Bosserhoff, 2007; Soengas et al., 2001; van der Velden et al., 2003). Table 4 
shows some genes affected by promoter DNA hypermethylation in melanoma. For example, 
CDKN2A is a major gene involved in the pathogenesis of melanoma. It is the most 
frequently mutated gene inherited in familial cutaneous melanoma (Palmieri et al., 2009; 
Sigalotti et al., 2010). Freedberg et al (2008) showed that aberrant promoter DNA 
hypermethylation at CDKN2A locus independently affects the tumor suppressors p16INK4A 
and p14ARF, which function in the pRB and p53 pathways, respectively. In human 
melanoma, p16INK4A and p14ARF are methylated.  
 
Gene Pathway Reference
APAF1(apoptotic protease activating 
factor 1) 
Apoptosis (Soengas et al., 2001)  
MT2A (methallothionein 2A) Apoptosis (Gallagher et al., 2005) 
HSPB1 (heat shock 27 kDa protein) Apoptosis (Gallagher et al., 2005)  
MAGE-A1(melanoma antigen, family A1) Immune recognition 
(De Smet et al., 1996; Karpf et 
al., 2004; Sigalotti et al., 2010) 
ER-ǂ (estrogen receptor alpha) Signaling (Mori et al., 2006) 
WFDC1 (wap 4-disulfide core domain 1) Proliferation (Muthusamy et al., 2006) 
CDKN1B (cyclin-dependent kinase 
inhibitor 1B 
Cell cycle (Worm et al., 2000) 
CDKN1C (cyclin-dependent kinase 
inhibitor 1C) 
Cell cycle (Shen et al., 2007) 
APC (adenomatous polyposis coli gene) 
Cell fate 
determination
(Worm et al., 2004) 
GDF15 (growth/differentiation factor 15) Differentiation (Muthusamy et al., 2006) 
TPM1 (tropomyosin 1) 
Anchorage-
independent growth
(Liu et al., 2008) 
MIB2 (skeletrophin) 
Cell fate 
determination
(Takeuchi et al., 2006) 
MGMT (06-methylguanine-DNA-
methyltransferase)
DNA repair (Hoon et al., 2004) 
CDH1 (E-cadherin) Invasion/metastasis (Liu et al., 2008)
CDH8 (cadherin 8) Invasion/metastasis (Muthusamy et al., 2006) 
Table 4. Genes with an altered DNA methylation status in melanoma 
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3.1 Clinical applications of DNA methylation 
DNA methylation is a reversible epigenetic event and can be nullified by specific DNA 
demethylating agents (DNA methyltransferase inhibitors).  Several ongoing clinical trials 
are conducted to investigate their clinical effectiveness and safety in melanoma patients 
(Table 3). In these studies, DNA demethylating agents 5-azacytidine (Vidaza) and 5-aza-2-
deoxycytidine (decitabine, Dacogen) are the most intensively studied. Azacytidine is a 
pyrimidine nucleoside analog of cytidine, and decitabine is a cytosine nucleoside (cytidine) 
analog. These epigenetic agents were approved by the FDA for the treatment of 
myelodysplastic syndromes and acute myeloid leukemia. Agents that inhibit DNA 
methyltransferases can reactivate silenced genes and induce apoptosis of cancerous cells 
(Howell et al., 2009). Since epigenetic modifications affect cellular pathways, epigenetic 
agents also display pleiotropic activities (Howell et al., 2009). In a phase I trial, Gollob et al. 
(2006) found that a low dose of 5-aza-2'-deoxycytidine (decitabine) can be safely 
administered with high-dose interleukin to cancer patients and has antitumor activity in 
melanoma. The inclusion of decitabine resulted in DNA hypomethylation. In addition, 
Appleton et al. (2007) showed that decitabine reduces DNA methylation and can be 
combined safely with carboplatin for the treatment of melanoma. 
In addition to therapeutic applications, modifications of DNA methylation may serve as 
biomarkers in clinical use for melanoma (Howell et al., 2009). Mori et al. (2006) showed that 
methylated ER-ǂ can be detected in paraffin-embedded primary and metastatic melanoma 
tumors. In addition, methylated ER-ǂ DNA was detected in the serum of melanoma patients 
with AJCC stage I to IV disease. Methylated ER-ǂ was detected in 42% of stage III and 86% 
of stage IV metastatic melanomas. Serum methylated ER-ǂ is an unfavorable prognostic 
factor. Liu et al (2008) found that SOCS1, SOCS2, RARǃ2, DcR1, and DcR2 genes were the 
most frequently methylated genes in melanoma. The investigators also found that RECK, 
IRF7, PAWR, DR5, and Rb were not methylated in melanoma although these genes were 
found to be highly methylated in other cancers (Howell et al., 2009; Liu et al., 2008), 
suggesting that different cancers have distinct methylated genes. This is important since 
biomarkers must be specific and be able to differentiate between different forms of 
malignancies.  
4. Conclusions and future perspectives 
Melanoma is a complex disease that is caused by aberrant genetic and epigenetic events. 
Epigenetic modifications play a significant role in the biology of melanoma, and epigenetic 
therapy emerges as a promising treatment modality for melanoma as well as for dignostic 
developments for the malignancy. A major difference between the two events is that 
epigenetic changes can be reversed by chemical and/or environmental modalities. Histone 
modifications and DNA methylation are extensively studied epigenetic events that affect the 
expression of genes. Currently, four epigentic agents have been approved by the U.S. FDA 
for hematologic malignancies and many HDACIs and DNMTIs are being investigated in 
clinical trials for solid tumors, such as melanoma. However, there have not been any FDA-
approved epigenetic agents for solid tumors. Consequently, further investigations are 
required to find successful treatment strategies or protocols involving epigenetic agents. 
Future developments would address the issues of systemic toxicities, nonspecific epigenetic 
effect, and low bioavailability. In addition, a promising strategy is combination therapy. In 
tumors, DNA methylation and histone acetylation can act synergistically to silence tumor 
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suppressor genes. This approach could potentially enhance the reversal of epigenetic 
silencing. Although in its infancy, epigenetic therapy has been shown to be an effective 
treatment modality for cancers, as evident by the approval of 4 epigenetic drugs by the U.S. 
FDA. Encouraging results from preclinical and clinical trials prompts further investigations 
into designing new drugs or strategy that are more suitable for epigenetic therapies for 
melanoma patients, with the goal of improving patient outcomes. 
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